• 한국영양학회:학술대회논문집
• /
• 한국영양학회 2001년도 춘계연합학술대회 초록
• /
• pp.310.2-310
• /
• 2001

• 한국자기학회:학술대회 개요집
• /
• 한국자기학회 1999년도 추계연구발표회 논문개요집
• /
• pp.62-63
• /
• 1999

• 대한약학회:학술대회논문집
• /
• 대한약학회 2001년도 Proceedings of International Convention of the Pharmaceutical Society of Korea
• /
• pp.262.2-262.2
• /
• 2001

• Tuberculosis and Respiratory Diseases
• /
• 제76권5호
• /
• pp.218-225
• /
• 2014

Background: Small cell lung cancer (SCLC) is an extremely aggressive tumor with a poor clinical course. Although many efforts have been made to improve patients' survival rates, patients who survive longer than 2 years after chemotherapy are still very rare. We examined the baseline characteristics of patients with long-term survival rates in order to identify the prognostic factors for overall survivals. Methods: A total of 242 patients with cytologically or histologically diagnosed SCLC were enrolled into this study. The patients were categorized into long- and short-term survival groups by using a survival cut-off of 2 years after diagnosis. Cox's analyses were performed to identify the independent factors. Results: The mean patient age was 65.66 years, and 85.5% were males; among the patients, 61 of them (25.2%) survived longer than 2 years. In the multivariate analyses, CRP (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.25-6.06; p=0.012), TNM staging (HR, 3.29; 95% CI, 1.59-6.80; p=0.001), and progression-free survival (PFS) (HR, 11.14; 95% CI, 2.98-41.73; p<0.001) were independent prognostic markers for poor survival rates. Conclusion: In addition to other well-known prognostic factors, this study discovered relationships between the long-term survival rates and serum CRP levels, TNM staging, and PFS. In situations with unfavorable conditions, the PFS would be particularly helpful for managing SCLC patients.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
• /
• pp.344.3-345
• /
• 2002

For the development of novel anticancer agent. we have designed. synthesized. and tested novel 4-phenyl-1(N)-arylsulfonylimidazolidinones. As a result. much more potent cytotoxicities of these compounds against the various cancer cell lines than those of doxorubicin were demonstrated. Elaboration on aryl motif on sulfonyl moiety led us to find highly potent 4-phenyl-1-(N-acylindoline-5-sulfonyl)imidazolidinones. Among them, 4-phenyl-l- ［N-(p-aminobenzoyl)indoline-5-sulfonyl］imidazolidinone (PA) was proved to have good pharmacological profile. (omitted)

• 대한약학회:학술대회논문집
• /
• 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.1
• /
• pp.233.3-234
• /
• 2003

Novel arylsulfonylimidazolidinones were previously demonstrated to have broad and highly potent cytotoxicities against a wide range of cancer cell line. Among them 4-phenyl-l N-(p-aminobenzoyl)indoline-5-sulfonyl imidazolidinone (PA) was proved to have good pharmacological profile. Recently modification of indoline moiety of PA led us to find new analogs which show better pharmacological profiles compared to PA. (omitted)

• 대한약학회:학술대회논문집
• /
• 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
• /
• pp.354.3-355
• /
• 2002

Interleukin (IL)-5 appears to be one of the main proinflammatory mediators among a growing number of cytokines and chemokines that induce eosinophilic inflammation. Sophoricoside and their analogs isolated from Sophora japonica show relatively potent inhibitory activity of interleukin (IL)-5 as a small molecule. To identify structural requirements of this isoflavonone for its inhibitory activity against IL -5. isoflavonones. isoflavanones, and their glycosides were prepared and tested their inhibitory activity against IL-5. (omitted)

• 한국임상수의학회:학술대회논문집
• /
• 한국임상수의학회 2008년도 추계학술대회
• /
• pp.164-164
• /
• 2008

• 한국수정란이식학회:학술대회논문집
• /
• 한국수정란이식학회 2006년도 The 6th Intermational Symposium on Developmental Biotechnology
• /
• pp.54-55
• /
• 2006

• 대한약학회:학술대회논문집
• /
• 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.1
• /
• pp.233.1-233.1
• /
• 2003

Interleukin (IL)-5 appears to be one of the main proinflammatory mediators among a growing number of cytokines and chemokines that induce eosinophilic inflammation. Sophoricoside and their analogs isolated from Sophora japonica show relatively potent inhibitory activity of interleukin (IL)-5 as a small molecule. Initial attempt to identify the structural requirement of this isoflavonone led to find new chalcones to exhibit the inhibitory activity of IL -5. (omitted)